NeuroSense Therapeutics Announces 1-for-20 Reverse Share Split

On September 9, 2026, NeuroSense Therapeutics Ltd. announced a 1-for-20 reverse share split of its ordinary shares. This corporate action will consolidate every twenty existing ordinary shares into one new ordinary share, with no par value. The company’s ordinary shares are expected to begin trading on a split-adjusted basis on the Nasdaq Capital Market starting Monday, September 14, 2026. The reverse split will significantly reduce the number of issued and outstanding ordinary shares from approximately 37,938,036 to 1,896,902 shares. No fractional shares will be issued; instead, any fractional interests will be rounded up to the nearest whole share. Additionally, the company will implement proportionate adjustments to the exercise prices and the number of shares underlying all outstanding warrants and options. While the issued share count will decrease, the company’s authorized share capital remains unchanged. The new CUSIP number for the ordinary shares following the split will be M74240207. This filing is incorporated by reference into several of the company's existing Registration Statements.